Tvardi Therapeutics heads into its May 14 earnings print with analysts turning more negative and short sellers trimming — a setup that tells two different stories about where the stock goes from here.
The clearest recent signal came from the Street. Barclays downgraded TVRD to Underweight on April 20, cutting its target from $4 to $3 — below the current price of $3.14. The same analyst had trimmed the target from $5 to $4 just weeks earlier on April 1, and Piper Sandler followed with a parallel cut to $3 on that same date. The direction of travel is unambiguous: two firms that initiated at $61 and $78 back in mid-2025 have spent the past six months relentlessly reducing expectations. BTIG remains the lone bull, reiterating Buy with a $15 target on April 1, but that sits so far above the cluster of $3–$4 targets that it reads as an outlier rather than a consensus anchor. The mean price target of $8.17 is effectively a legacy figure dragged up by those older initiations; the actionable range from active coverage is $3–$15, with most of the recent momentum pointing to the lower end.
The bear case is straightforward. Cash runs out by end-2026, TTI-101 is unproven as a monotherapy in later treatment lines, and the company needs more data before dosing strategy is finalised. The bull case rests on TTI-109 — the prodrug with better delivery and IP protection — where preliminary data are due in Q2 2026, potentially before or around the May 14 print. That data drop is the single most important catalyst for the stock right now.
Short interest has been moving in a direction that partially contradicts the bearish analyst tone. Bears have been covering, not piling in. Short interest as a percentage of free float has fallen from above 11% in late March to 8.3% now — a meaningful retreat of roughly 25% from the highs. That said, 8.3% still represents a meaningfully shorted name, and the past week has seen a modest rebuild, with the estimate up about 7.5% week-on-week. The borrow market reflects the ambiguity: cost to borrow has halved over the week to 2.4% after spiking above 4% mid-April, and borrow availability remains loose enough that new short positions are not constrained. The ORTEX short score of 69.3 — elevated but not extreme — is consistent with a stock that is watched closely by shorts but where conviction has been fading.
Options positioning has swung sharply toward calls. The put/call ratio is running near its 52-week low at 0.027, far below its 20-day average of 0.26, which likely reflects extremely thin options volume on the put side rather than aggressive bullish conviction. The PCR spiked to above 1.3 in mid-April — coinciding with the Barclays downgrade period — before collapsing back. It is a noisy signal for a small-cap biotech with limited options liquidity.
Earnings history offers a cautionary note. The last three prints all produced negative first-day reactions: -6.25% in March 2026, -4.95% in November 2025, and -1.95% following the November 2025 period. The lone positive print — a +8.6% move in August 2025 — came with a five-day follow-through of +18%. The pattern is consistent with a stock where negative prints linger and positive ones can run. With Q2 TTI-109 data potentially arriving around the same time as the May 14 event, the binary nature of the upcoming catalyst is wider than a typical quarterly earnings release.
What to watch: whether TTI-109 preliminary data arrive before or alongside the May 14 print, and whether Barclays' freshly-minted Underweight prompts any further downgrades from the currently neutral-leaning consensus.
See the live data behind this article on ORTEX.
Open TVRD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
